Investigating CAR-T Treatment Access for Multiple Myeloma Patients Using Real-World Evidence.

Journal: medRxiv : the preprint server for health sciences
Published Date: Apr 19, 2025

Abstract

OBJECTIVE: Multiple myeloma (MM) is the second most common hematologic malignancy in the U.S., with Black patients being diagnosed at twice the rate of White patients. MM treatment options are limited and ineffective, but CAR-T therapies show promise. However, their limited availability results in disparities in access. This study aimed to explore disparities in Multiple Myeloma disease risk and CAR-T therapy access.

Authors

  • Jaysón Davidson
    Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA.
  • Anupama Kumar
    Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA.
  • Ayan Patel
    Center for Data-driven Insights and Innovation, University of California Health, Oakland, CA.
  • Irene Y Chen
    Computational Precision Health, University of California San Francisco, San Francisco, CA, University of California Berkeley, Berkeley, CA.
  • Atul J Butte
    Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA.
  • Travis Zack
    Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals